The association between CD99 and LMP-1 expression in nasopharyngeal carcinoma

Experimental Oncology

Volumn 28, Issue 1, 2006, Pages 40-43

  Kim, H S ^a   Kim, J S ^a   Park, J T ^a   Lee, M C ^a   Juhng, S W ^a   Cho, J H ^b   Park, C S ^a  

^a Chonnam National University Medical School   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

CD99; Epstein Barr virus; Hodgkin lymphoma; Latent membrane protein 1; Nasopharyngeal carcinoma

Indexed keywords

LATENT MEMBRANE PROTEIN 1; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN CD99; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE CLASSIFICATION; EPITHELIUM TUMOR; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOID TISSUE; MALE; NASOPHARYNX CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; WORLD HEALTH ORGANIZATION;

ANTIGENS, CD; CELL ADHESION MOLECULES; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS, SQUAMOUS CELL; RESPIRATORY MUCOSA;

EID: 33646051222     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004; 31: 794-801.
2. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 1996; 7: 165-74.
3. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995; 10: 549-60.
4. Wang C, Ai M, Ren W, Xiao H, Li X, Tang F, Gu H, Yi W, Weng X, Deng X, Cao Y. Epstein-Barr virus encoded latent membrane protein 1 induces TRAF1 expression to promote anti-apoptosis activity via NF-kappaB signaling pathway in nasopharyngeal carcinoma. Chin Med J (Engl) 2003; 116: 1022-8.
5. Gelin C, Aubrit F, Phalipon A, Raynal B, Cole S, Kaczorek M, Bernard A. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J 1989; 8: 3253-9.
6. Choi EY, Park WS, Jung KC, Kim SH, Kim YY, Lee WJ, Park SH. Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. J Immunol 1998; 161: 749-54.
7. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol 1999; 193: 17-23.
8. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol 2000; 53: 248-54.
9. Kim SH, Choi EY, Shin YK, Kim TJ, Chung DH, Chang SI, Kim NK, Park SH. Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2) Blood 1998; 92: 4287-95.
10. Kim SH, Shin YK, Lee IS, Bae YM, Sohn HW, Suh YH, Ree HJ, Rowe M, Park SH. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 2000; 95: 294-300.
11. Lee IS, Kim MK, Choi EY, Mehl A, Jung KC, Gil MC, Rowe M, Park SH. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB. Blood 2001; 97: 3596-604.
12. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci USA 1974; 71: 4737-41.
13. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 1051-65.
14. Murono S, Yoshizaki T, Park CS, Furukawa M. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology 1999; 34: 432-8.
15. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431-41.
16. Knecht H, Berger C, McQuain C, Rothenberger S, Bachmann E, Martin J, Esslinger C, Drexler HG, Cai YC, Quesenberry PJ, Odermatt BF. Latent membrane protein 1 associated signaling pathways are important in tumor cells of Epstein-Barr virus negative Hodgkin's disease. Oncogene 1999; 18: 7161-7.
17. Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immuneregulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for membrane protein. Mol Immunol 1989; 26: 181-8.
18. Banting GS, Pym B, Darling SM, Goodfellow PN. The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein. Mol Immunol 1989; 26: 181-8.